VGI Health Technology : June 2022 Quarterly Report

NSX Quarterly Report

Quarterly Report

Name of entity

VGI Health Technology Ltd

ABN		Quarter ended ("current quarter")
35 111 082 485		June 2022

Consolidated statement of cash flows

			Current quarter	Year to date
Cash flows related to operating activities	$A'000	(12 months)
				$A'000
1.1	Receipts from customers	(2)	10
1.2	Payments for
	(a)	staff costs	(207)	(847)
	(b)	advertising and marketing	-	(1)
	(c)	research and development	(510)	(1,299)
	(d)	leased assets	-	-
	(e)	other working capital	217	187
1.3	Dividends received	-	-
1.4	Interest and other items of a similar nature	-	-
	received
1.5	Interest and other costs of finance paid	(45)	(85)
1.6	Income taxes paid	-	-
1.7	Other (provide details if material)	-	315
	Net operating cash flows	(547)	(1,720)

Page 1

NSX Quarterly Report

		Current quarter	Year to date
		$A'000	(12months)
			$A'000
1.8	Net operating cash flows (carried forward)	(547)	(1,720)
	Cash flows related to investing activities
1.9	Payment for acquisition of:
	(a) businesses (item 5)	-	-
	(b) equity investments	-	-
	(c) intellectual property	(8)	(59)
	(d) physical non-current assets	-	-
	(e) other non-current assets	-	-
1.10	Proceeds from disposal of:
	(a) businesses (item 5)	-	-
	(b) equity investments	-	-
	(c) intellectual property	-	-
	(d) physical non-current assets	-	-
	(e) other non-current assets	-	-
1.11	Loans to other entities	-	-
1.12	Loans repaid by other entities	-	-
1.13	Other (provide details if material)	-	-
		(8)	(59)
	Net investing cash flows
1.14	Total operating and investing cash flows	(555)	(1,779)
	Cash flows related to financing activities
1.15	Proceeds from issues of shares, options,	-	-
	etc.
1.16	Proceeds from sale of forfeited shares	-	-
1.17	Proceeds from borrowings	551	1,583
1.18	Repayment of borrowings	-	-
1.19	Dividends paid	-	-
1.20	Other (conversion of convertible notes)	-	-
	Net financing cash flows	551	1,583
	Net increase (decrease) in cash held	(4)	(196)
1.21	Cash at beginning of quarter/year to date	35	227
1.22	Exchange rate adjustments to item 1.20	-	-
1.23	Cash at end of quarter	31	31

Page 2

NSX Quarterly Report

Payments to directors of the entity and associates of the directors

Payments to related entities of the entity and associates of the related entities

		Current quarter
		$A'000
1.24	Aggregate amount of payments to the parties included in item 1.2	(145)
1.25	Aggregate amount of loans to the parties included in item 1.11	-

1.26 Explanation necessary for an understanding of the transactions

During the Quarter ended 30 September 2021, VTL received $315,137 in Research and Development tax incentives from the Australian Taxation office. This was related to the Research and Development expenditure for the year ended 30 June 2020.

Non-cash financing and investing activities

1. Details of financing and investing transactions which have had a material effect on consolidated assets and liabilities but did not involve cash flows
   VTL entered executed a binding agreement on 5 April 2022 for the sale of its wholly owned subsidiary Invictus BioPharma Pty Ltd (IBP). At an extraordinary General meeting held on 3 June 2022, the shareholders approved the sale of IBP. In line with AASB 5, the assets and liabilities of IBP and its subsidiaries were re-allocated in the balance sheet to be shown as an Asset held for sale. The value of the Asset held for sale is $3,399,520. VTL also recognised a loss on initial recognition of Assets held for sale of $5,106,720.
2. Details of outlays made by other entities to establish or increase their share in businesses in which the reporting entity has an interest
   N/A

Financing facilities available

Add notes as necessary for an understanding of the position. (See AASB 1026 paragraph 12.2).

		Amount available	Amount used
		$A'000	$A'000
3.1	Loan facilities	737	1,545
3.2	Credit standby arrangements
-	-

Page 3

NSX Quarterly Report

Reconciliation of cash

Reconciliation of cash at the end of the quarter	Current quarter	Previous quarter
(as shown in the consolidated statement of cash	$A'000	$A'000
flows) to the related items in the accounts is as
follows.
4.1	Cash on hand and at bank	31	35
4.2	Deposits at call
4.3	Bank overdraft
4.4	Other (provide details)
	Total: cash at end of quarter (item 1.22)	31	35

Acquisitions and disposals of business entities

			Acquisitions	Disposals
			(Item 1.9(a))	(Item 1.10(a))
5.1	Name of entity		N/A	N/A
5.2	Place	of
	incorporation	or
	registration

1. Consideration for
   acquisition or disposal
2. Total net assets
3. Nature of business

Compliance statement

1. This statement has been prepared under accounting policies which comply with accounting standards as defined in the Corporations Act (except to the extent that information is not required because of note 2) or other standards acceptable to NSX.
2. This statement does give a true and fair view of the matters disclosed.

Sign here:	............................................................ Date: 29 July 2022
	(Company secretary)
Print name:	Catriona Glover

Page 4

NSX Quarterly Report

Notes

1. The quarterly report provides a basis for informing the market how the entity's activities have been financed for the past quarter and the effect on its cash position. An entity wanting to disclose additional information is encouraged to do so, in a note or notes attached to this report.
2. The definitions in, and provisions of, AASB 1026: Statement of Cash Flows apply to this report except for the paragraphs of the Standard set out below.

• 6.2 - reconciliation of cash flows arising from operating activities to operating profit or loss
• 9.2 - itemised disclosure relating to acquisitions
• 9.4 - itemised disclosure relating to disposals
• 12.1(a) - policy for classification of cash items
• 12.3 - disclosure of restrictions on use of cash
• 13.1 - comparative information

3. Accounting Standards. NSX will accept, for example, the use of International Accounting Standards for foreign entities. If the standards used do not address a topic, the Australian standard on that topic (if any) must be complied with.

Page 5